Callio Therapeutics develops next-generation, multi-payload antibody-drug conjugates (ADCs).
Callio Therapeutics has raised $187.0M in total funding. The most recent round was Series A. The last funding was announced in March 2025.
Callio Therapeutics's investors include Norwest Venture Partners, Jeito Capital, Novo Holdings, EDBI, Omega Funds.
Callio Therapeutics is headquartered in Seattle, United States.
Callio Therapeutics develops next-generation, multi-payload antibody-drug conjugates (ADCs).
Callio Therapeutics is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Callio Therapeutics — Funding & Investors." VCBacked, March 3, 2025, https://www.vcbacked.co/company/callio-therapeutics. Accessed September 9, 2026.
VCBacked. (2025). Callio Therapeutics — Funding & Investors. Retrieved September 9, 2026, from https://www.vcbacked.co/company/callio-therapeutics
{{cite web |title=Callio Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/callio-therapeutics |website=VCBacked |access-date=September 9, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated